scholarly journals Effects of Acute and Chronic Stretching on Pain Control

2021 ◽  
Vol 10 (4) ◽  
pp. 150-159
Author(s):  
David G. Behm ◽  
Anthony D. Kay ◽  
Gabriel S. Trajano ◽  
Shahab Alizadeh ◽  
Anthony J. Blazevich

ABSTRACT While muscle stretching has been commonly used to alleviate pain, reports of its effectiveness are conflicting. The objective of this review is to investigate the acute and chronic effects of stretching on pain, including delayed onset muscle soreness. The few studies implementing acute stretching protocols have reported small to large magnitude decreases in quadriceps and anterior knee pain as well as reductions in headache pain. Chronic stretching programs have demonstrated more consistent reductions in pain from a wide variety of joints and muscles, which has been ascribed to an increased sensory (pain) tolerance. Other mechanisms underlying acute and chronic pain reduction have been proposed to be related to gate control theory, diffuse noxious inhibitory control, myofascial meridians, and reflex-induced increases in parasympathetic nervous activity. By contrast, the acute effects of stretching on delayed onset muscle soreness are conflicting. Reports of stretch-induced reductions in delayed onset muscle soreness may be attributed to increased pain tolerance or alterations in the muscle's parallel elastic component or extracellular matrix properties providing protection against tissue damage. Further research evaluating the effect of various stretching protocols on different pain modalities is needed to clarify conflicts within the literature.

2005 ◽  
Vol 83 (12) ◽  
pp. 1137-1145 ◽  
Author(s):  
L.C. Loram ◽  
D. Mitchell ◽  
A. Fuller

We assessed the effect of rofecoxib, a cyclo-oxygenase-2 inhibitor, and tramadol, a centrally acting analgesic, on both delayed-onset muscle soreness (DOMS) and experimentally induced ischaemic pain. We induced DOMS in 10 male and 5 female healthy volunteers by downhill running for 30 min at a 12% decline and a speed of 9 km·h–1. We also induced ischaemic pain by finger movements with an arterial tourniquet around the arm. In a randomized, double-blind crossover format, we administered rofecoxib (50 mg, daily), tramadol (50 mg, 3 times per day), and a placebo (orally for 3 days), starting immediately after exercise. A 100 mm visual analogue scale (VAS) and McGill pain questionnaire were used to describe muscle soreness and ischaemic forearm pain 24 h after the exercise. The pressure pain threshold (PPT) in the thigh and ischaemic pain tolerance in the forearm were measured before exercise and 24 and 72 h after exercise. PPT decreased 24 h after exercise, compared with pre-exercise values (ANOVA, p < 0.05), but neither drug had any significant effect on the PPT. Neither rofecoxib nor tramadol had any effect on time of ischaemia tolerated or amount of finger activity during ischaemia. The VAS and pain-rating index, for both muscle soreness and experimental ischaemic pain, were not affected significantly by either drug. Both DOMS and ischaemic pain share peripheral and central mechanisms, yet neither are attenuated by rofecoxib or tramadol.


1986 ◽  
Vol 5 (3) ◽  
pp. 605-614 ◽  
Author(s):  
William C. Byrnes ◽  
Priscilla M. Clarkson

2020 ◽  
Vol 77 ◽  
pp. 231-235
Author(s):  
Camila C. da Silva ◽  
Álvaro S. Machado ◽  
Gislaine R. dos Santos ◽  
Helen L. Schimidt ◽  
Marcos R. Kunzler ◽  
...  

2017 ◽  
Vol 49 (5S) ◽  
pp. 947
Author(s):  
Michael E. Rogers ◽  
Jolaolu M. Jimoh ◽  
Sri Valli Chekuri ◽  
Duane C. Button

Sign in / Sign up

Export Citation Format

Share Document